MEDRAD Inc., of Warrendale, Penn., yesterday announced the first installation of its Intego PET Infusion System at the University of Pittsburgh Medical Center (UPMC), Hillman Cancer Center.

The company has partnered with IBA Molecular, which will supply UPMC with fluorodeoxyglucose (FDG) in a multi-dose vial housed in a specially designed Tungsten vial shield. 

Automating the administration of FDG for PET/CT imaging procedures, the Intego automatically extracts a patient dose from a multi-dose vial and administers the dose, via infusion, directly to the patient. This process aims to minimize the need for manual dose preparation and associated handling, as well as protect the technologist from the corresponding radiation exposure.